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Background: Pyoderma gangrenosum (PG) is a rarely diagnosed ulcerative neutrophilic dermatosis with unknown
origin that has been poorly characterized in clinical studies so far. Consequently there have been significant
discussions about its associated factors and comorbidities. The aim of our multicenter study was to analyze current
data from patients in dermatologic wound care centers in Germany in order to describe associated factors and
comorbidities in patients with PG.
Methods: Retrospective clinical investigation of patients with PG from dermatologic wound care centers in Germany.
Results: We received data from 259 patients with PG from 20 different dermatologic wound care centers in Germany.
Of these 142 (54.8%) patients were female, 117 (45.2%) were male; with an age range of 21 to 95 years, and a mean of
58 years. In our patient population we found 45.6% with anemia, 44.8% with endocrine diseases, 12.4% with internal
malignancies, 9.3% with chronic inflammatory bowel diseases and 4.3% with elevated creatinine levels. Moreover 25.5%
of all patients had a diabetes mellitus with some aspects of potential association with the metabolic syndrome.
Conclusions: Our study describes one of the world’s largest populations with PG. Beside the well-known association
with chronic bowel diseases and neoplasms, a potentially relevant new aspect is an association with endocrine
diseases, in particular the metabolic syndrome, thyroid dysfunctions and renal disorders. Our findings represent
clinically relevant new aspects. This may help to describe the patients’ characteristics and help to understand the
underlying pathophysiology in these often misdiagnosed patients.
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Pyoderma gangrenosum (PG) is a so far poorly character-
ized, challenging destructive neutrophil-mediated auto-
inflammatory disease with an incidence of 0.3-1.0/100.000
[1-5]. Langan et al. showed in 2012 an adjusted incidence
rate standardized to European standard populations of
0.63 (95% confidence interval (CI) 0.57-0.71) per 100,000
person-years [6]. Even if the PG is a diagnosis of exclusion,* Correspondence: joachim.dissemond@uk-essen.de
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reproduction in any medium, provided the orfor its proper identification various primary and secondary
criteria should be fulfilled (Table 1). The clinical appearance
is marked by the sudden onset of erythematous nodules
or sterile pustules that rapidly develop into very painful
ulcerations with violaceous undermined borders. Patients
often report that primary lesions appear after trauma such
as insect bites, excoriations or surgical interventions. The
etiology of PG is still unclear. Clinical investigations have
reported abnormal cellular immunity with anergy to recall
antigens or an imbalance between helper T- and suppressor
T-cells. Brooklyn et al. showed by the examination of T-cell
receptor repertoire in cells taken from the peripheral blood
and from PG biopsies that T-cells play an integral role inral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Modified diagnostic criteria for PG [1,18-23]
I. main criteria Primary sterile pustule or ulcer with livid, undermined wound-border [1,14,15,18-21]
Exclusion of other relevant differential diagnoses like chronic venous/arterial leg ulcer, pyodermatitis, vasculitis [1,14,15,18-20]
II. additional criteria Histology of the wound-border: neutrophilic infiltration of the dermis with signs of vasculitis and accumulation of
immunglobulins and/or complement factors beside the vessels [14,15,20]
Existence of relevant, associated concomitant diseases like chronic inflammatory bowel diseases, arthropathies, haematological
disorders, neoplasia, endocrine dysfunctions, metabolic syndrome [14,15]
Response to a systemic immunosuppressive therapy or no response to a conventional ulcer-therapy [15,20]
Triggering of a PG by pathergy-phenomenon [14,15,20]
Extremely painful ulcer (VAS > 4 points) [14,15]
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trafficking to the skin under the influence of an anti-
genic stimulus [7]. An impairment of integrin effects
on neutrophilic granulocytes, abnormal granulocyte
tracking and monoclonal gammopathy involving IgA,
IgG and IgM in up to 15% of patients has been discussed
[8,9]. A currently investigated new aspect is the proline-
rich, glutamic acid-rich, serine-rich and threonine-rich
(PEST) family of protein tyrosine phosphatases as a critical
regulator of cell adhesion and migration. The PSTPIP1 is
a cytoskeleton-associated adaptor protein that links
PEST-type phosphatases to their substrates. This pathway
seems to be involved in diseases related to PG such as
chronic inflammatory bowel disease and aseptic abscess
syndrome [10,11]. Some case-reports about an auto-
somal dominant, auto-inflammatory disease, known as
PAPA-syndrome (pyogenic arthritis, PG and acne) showed
an association to mutations in the PSTPIP1/CD2BP1
gene on chromosome 15q. These mutations cause a
hyper-phosphorylated PSTPIP1 protein and alter its
participation in activation of the inflammasome with
elevated interleukin-1 beta (IL-1β) release [12,13].
Demidowich et al. also investigated and confirmed these re-
sults by the analysis of five patients with PAPA syndrome
and showed that mutations in PSTPIP1 are incompletely
penetrant and variably expressed and neutrophil granule
proteins were markedly elevated ex vivo and in the plasma
[14]. The symptoms pyoderma gangrenosum, acne, and
suppurative hidradenitis are summarized in the acronyme
PASH syndrome as a new entity in the spectrum of auto-
immunolatory syndromes. PASH syndrome is similar to
PAPA syndrome but it differs in lacking the associated
pyogenic arthritis. Mutations in the PSTPIP1 gens
were excluded so far [15,16]. But in a currently published
case report a p.E277D missense mutation of the PSTPIP1
gene was described as PAPASH syndrome [17].
All these findings lead to a new effective targeted
treatment with recombinant interleukin (IL)-1β receptor
antagonists beside the already proven therapy with
TNF-α inhibitors for blocking the key molecule of the
inflammatory response [11].Current knowledge about the pathogenesis of PG, as well
as potential comorbidities is very limited and based on case
series reports and results from studies with up to only 103
patients. Based on this information, some current textbooks
report an association with internal diseases such as chronic
inflammatory bowel disease, hematological disorders, neo-
plasia or other autoimmune diseases such as rheumatoid
arthritis in up to 80% of patients [24]. The underlying
original data are very heterogenous [1-3]. Therefore the
aim of our multicenter study was to analyze current data
from patients in dermatologic wound care centers in
Germany in order to characterize associated factors and
comorbidities in patients with PG.
Material and methods
Patients
This study was performed in compliance with the Helsinki
Declaration by following ethical principles for medical
research involving human subjects, including research on
identifiable human material and data. After systematic
literature analysis we developed a questionnaire and be-
ginning in August 2010 advertised and recruited participa-
tion for this study among members of the working group
for wound-healing (Arbeitsgemeinschaft Wundheilung,
AGW) of the German Dermatology Society (Deutsche
Dermatologische Gesellschaft, DDG). Data up to February
2011 were included in this analysis of patients with a
diagnosed PG from 20 specialized dermatologic wound
care centers in Germany. Positive written consent was
obtained from each subject who participated in the study.
The inclusion criteria for the patients in this investigation
were the modified main and additional diagnostic criteria
for PG as given in Table 1. After excluding clinically
relevant differentials, the diagnosis has to be based in
the centers on the patient medical history, histologic
analysis of a biopsy sample, confirmation of the typical clin-
ical appearance of PG lesions with a violaceous undermined
border and the lack of response to conventional wound-
therapy. The diagnoses were confirmed by selected experts
from Essen (n = 49), Hamburg (n = 44), Duisburg (n = 29),
Tübingen (n = 23), Düsseldorf (n = 20), Münster (n = 13),
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(n = 9), Goerlitz (n = 7), Krefeld (n = 6), Ulm (n = 5),
Cologne (n = 5), Dresden (n = 5), Göttingen (n = 5),
Munich (n = 3), Alzenau (n = 3) and Lüdenscheid (n = 2)
according to the best available diagnostic criteria. These
diagnostic criteria are based on main criteria: presence of a
primary sterile pustule or ulcer with livid, undermined
wound-border, the exclusion of other differential diagnoses
and at least one additional criterion (Table 1). Further
studies will follow to validate and verify the clinical
use of these proposed diagnostic criteria.
Associated factors and comorbidities
According to the clinical records, concomitant diseases
were classified in this questionnaire as gastrointestinal,
rheumatoid, hematologic, or endocrine disease, as well as
infectious disease, neoplasia, underlying immune deficiency
and obesity. Obesity was defined as body mass index
(BMI) >30.0 kg/m2. Pathologic serologic results and
autoantibody detection were also recorded. Moreover,
we collected demographic data such as gender, age,
trigger factors and pain. Pain was measured by using a
visual analogue scale (VAS) which ranged from 0 (no pain)
to 10 (most severe pain imaginable).
Statistical analysis
All data were recorded for each patient in an electronic
table and statistically analyzed with the program Excel®
from Microsoft® Office 2011.
Results
Patients
We received clinical data from 259 patients with PG from
20 different dermatologic wound care centers in Germany.
Of these patients 142 (54.8%) were female, 117 (45.2%)Figure 1 Age pattern of male and female patients with PG. Blue = mawere male. The age range for initial manifestation of
PG was 21 to 95 years with a mean of 58 years. The
average age of women was 60 years and that for men
54 years (Figure 1).
Trigger
In 111 (42.8%) patients the onset of PG followed
minor trauma or surgical intervention which was defined
as a trigger. In 148 (57.2%) patients PG developed
spontaneously without a relevant identified trigger.
Pain
In this study patients described pain with a minimum of
2 points and a maximum of 10; the average score of
the VAS scale was 6.2 when patients presented to the
dermatologic wound care centers.
Comorbidities
The comorbidities found in this study in patients with PG
are summarized in Table 2. As a main finding of this
investigation there is a potential association between
endocrine diseases and the onset of PG. Diabetes mellitus
was found in 25.5% of patients and thyroid disorders in
11.2%. As expected, inflammatory parameters were elevated
in a large number of cases. Table 3 shows the comparison
of our study data with the prevalence in median age groups
of the several possible associated comorbidities.
Discussion
In the last few years there is increasing evidence that PG
is not merely an isolated skin disease but instead may be a
cutaneous manifestation of a generalized inflammatory
reaction, which is associated with other internal diseases.
It has been discussed that, due to a chronic systemic
Th1-mediated inflammatory reaction, there is an increasedle patients, red = female patients.
Table 2 Comorbidities and pathologic serologic




Gastrointestinal diseases 66 22.5 (overall)
Chronic active hepatitis 11 16.7
Ulcerative colitis 17 25.8
Crohn’s disease 7 10.6
Diverticulosis 9 13.6
Gastric disorders 13 19.7
Gastric/duodenal ulcer 4 6.0
Gastrointestinal polyps 2 3.0
Steatohepatitis 1 1.5
Others 2 3.0
Arthropathy 48 18.5 (overall)
Rheumatoid arthritis 24 50.0
a) seropositive 21 43.8
b) seronegative 3 6.3
Arthrosis 17 25.8
Ankylosing spondylitis 2 4.1
Psoriasis arthropathy 3 6.3
Osteoporosis 2 4.1
Haematological diseases 10 3.9 (overall)
Leukemia 3 30.0
a) AML 1 10.0
b) CML 2 20.0
Lymphoma (T-cell) 2 20.0
Multiple myeloma 2 20.0
Macroglobulinemia 3 30.0
Neoplasia 22 8.5 (overall)
Breast cancer 6 27.3
Lung cancer 3 13.6
Prostate cancer 3 13.6
Malignant melanoma 3 13.6
Hepatocellular carcinoma 2 9.1
Ovarian cancer 2 9.1
Colorectal cancer 1 4.5
Laryngeal cancer 1 4.5
Glioblastoma 1 4.5
Endocrine disorders 95 36.7 (overall)
Diabetes mellitus 66 69.5
a) type II 60 63.2
b) type I 6 6.3
Thyroid disease 29 30.5
Hyperthyroidism 9 9.5
Hypothyroidism 18 19.0
Hashimoto’s thyroiditis 2 2.1
Table 2 Comorbidities and pathologic serologic
parameters in 259 patients with PG (Continued)
Serological parameters 181 69.9 (overall)
Anemia 118 65.2
Microcytic anaemia 28 15.5
Auto-antibodies 45 24.9
Anti-nuclear antibodies 30 16.6
C-reactive protein 181 100
Leukocytosis 117 64.6
Elevated creatinine 52 28.7
Renal failure 11 6.1
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patients the systemic inflammation with serological find-
ings of increased pro-inflammatory cytokines such as
TNF-α and L-6 leads to TNF-α-induced insulin resistance
and subsequently to a pre-diabetic state. The patients suffer
also from artherosclerosis and increased incidence of
cardiovascular events [18]. In psoriasis there has been a
paradigm shift away from viewing the disorder as a purely
cutaneous disease to a systemic “immune-mediated
inflammatory disease” (IMID). This group of diseases,
which is also referred to as TRECID (TNF-α related
chronic inflammatory diseases), includes psoriasis as
well as Crohn’s disease, rheumatoid arthritis, and in
current discussions maybe also PG [25]. All of these
diseases involve a chronic systemic inflammatory reaction
and respond clinically to TNF-α-antibodies.
The underlying data for current textbook chapters about
PG are case report series and very few scientific studies
with small numbers of patients [1-3,18-21,26-28]. In a
single center investigation from Germany, data from 44
patients with PG were analyzed [1]. The authors reported
an association between the onset of PG and autoimmune
disease such as ulcerative colitis or Crohn’s disease in 6.8%
(n = 3), and rheumatoid arthritis in 11.4%, while 20.4% had
a malignant internal neoplasia. Two other clinical studies
were published in 1985 and 2000 and included 86
patients [2,3]. Powell et al. performed a retrospective
analysis of patients at two dermatologic centers in the
United States (Table 4). They found 52.3% of all patients
had a potentially associated systemic disease; 32.5% had
an autoimmune disorder, 11.6% had ulcerative colitis,
9.3% patients had Crohn’s disease, and 11.6% patients had
rheumatoid arthritis. Neoplasms were reported in 15.1%
of patients and included monoclonal gammopathy,
myelodysplasia, Hodgkin’s lymphoma, POEMS syndrome
and IgA-myeloma. In this study numerous other factors
such as infectious gastrointestinal diseases, cutaneous
inflammation, and rare coagulation disorders were also
examined. One single center, retrospective study from
Table 3 Comparison of study data with prevalence in median age group according to current data from Germany
Our data Prevalence in median age group
Sex (m:f) 117:142; 55% female prevalence for PG: 0.3-1.0/100.000
(Germany: 1000:1040; 51% female)
Age (mean) 21-94 years (57.3 years)
(Germany, 2010: 44.3 years)
Associated inflammatory disorders
Arthrosis, non rheumatoid arthritis 17 (6.6%) female (45–65 years): 33%
male: (45–65 years): 25%
Rheumatoid arthritis 24 (9.3%) female (45–64 years): 8.6%
male (45–64 years): 5%
overall: 0.5-0.8%
Chronic inflammatory bowel disease Overall: 24 (9.3%) Crohn’s disease:
Crohn’s disease: 120-200/100.000
7 (2.7%) Ulcerative colitis:
Ulcerative colitis: 17 (6.6%) 160-250/100.000
Endocrine disorders
Thyroid disease 29 (11.2%) overall: 5.5%
female: 8.9%
male: 1.8%
Diabetes mellitus 66 (25.5%) international overall (20–79 years): 12%
German overall: 8.9%
Neoplasia 32 (12.4%) overall: 5-yr.-prevalence: 1.6%
10-yr.-prevalence: 2.4%
Solid neoplasms (overall) 22 (8.5%)
Breast cancer 6 (2.3%) female (50–59 years): 1-year-prevalence: 0.2%
Lung cancer 3 (1.6%) female: 50–59 years: 1-year-prevalence: 0.04%
male: 50–59 years: 1-year-prevalence: 0.07%
Prostate cancer 3 (1.6%) male overall: 1-year-prevalence: 0.1%
male (60–69 years): 1-year- prevalence: 0.5%
Melanoma 3 (1.6%) female (50–59 years): 1-year.-prevalence: 0.03%
male (50–59 years): 1-year life-prevalence: 0.02%
Hepatocellular carcinoma 2 (0.8%) overall: 7-8/100.000
Ovarian cancer 2 (0.8%) female (50–59 years): 1-year life-prevalence: 0.03%
Colon cancer 1 (0.4%) female (50–59 years): 1-year.-prevalence: 0.1%
male (50–59 years): 1-year-prevalence:
Laryngeal cancer 1 (0.4%) female: 1-year-prevalence: <0.01%
male: 1-year-prevalence: <0.1%
Glioblastoma multiforme 1 (0.4%) n.a.
Hematologic/hematopoetic neoplasia Leukemia, female:1-year-prevalence: 0.01%
AML 1 (0.4%)
CML 2 (0.8%) Leukemia, male:
Other 7 (2.8%) 1-year-prevalence: 0.01%
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systemic disease. Arthritis was diagnosed in 37%, chronic
inflammatory bowel disease in 36% and neoplasia, includingmonoclonal gammopathy and polycythemia vera in 17% of
all patients. Endocrine disorders like diabetes mellitus were
reported in only 2% of the patients.
Table 4 Comparative summarized data of patients from the so far largest published case studies for PG between












Patients 86 44 86 49 103 259
Sex (m:w) 1:1 1:2.1 1:1.3 1:1.5 1:3.1 1:1.2
Age (mean) 7-71 yrs. 11-80 yrs. 2-83 yrs. 22-95 yrs. 22-88 yrs. 21-94 yrs.
(n.r.) (50.3 yrs.) (48.4 yrs.) (59.7 yrs.) (51.6 yrs.) (57.3 yrs.)




28 (33%) n.r. 10 (12%) 1 (2%) 20 (19.4%) 17 (6.6%)
Rheumatoid arthritis n.r. 5 (11%) n.r. 3 (6%) 10 (9.7%) 24 (9.3%)
chronic inflammatory
bowel disease
31 (36%) 6 (14%) 18 (21%) 3 (6%) 35 (34%) 24 (9.3%)
Crohn: 14 (16%) Crohn: 3 (7%) Crohn: 8 (9%) Crohn: 1 (2%) Crohn: 17 (16.5%) Crohn: 7 (2.7%)
Ulcerat. col.:
17 (20%)
Ulcerat. col.: 3 (7%) Ulcerat. col.:
10 (12%)





Thyreoid disease 5 (6%) n.r. n.r. 7 (14%) 4 (3.9%) 29 (11.2%)
























solid neoplasms Bladder: 1 (1%) Glioblastoma mult.:
1 (2%)
n.r. Breast: 2 (4%) n.r. Breast: 6 (2.3%)
Colon: 2 (2%) Prostate: 1 (2%) Lung: 3 (1.2%)












AML 1 (1%) n.r. n.r. 0 1 (0.97%) 1 (0.4%)
CLL n.r. 1 (2%) n.r. 0 n.r. 0
CML n.r. 1 (2%) n.r. 2 (4%) n.r. 2 (0.8%)
Other
Myelodysplasia n.r. n.r. 3 (4%) 0 2 (1.9%) 0
Polycythemia rubra vera 1 (1%) n.r. n.r. 0 2 (1.9%) 0
Monoclonal gammopathy 9 (10%) n.r. 4 (5%) 2 (4%) 10 (9.7%) 3 (1.2%)
Plasmocytoma n.r. 1 (2%) 0 1 (1.0%) 2 (0.8%)
POEMS syndrome n.r. n.r. 1 (1%) 0 n.r. 0
Mycosis fungoides/ cutaneous
T-cell lymphoma
n.r. 1 (2%) n.r. 1 (2%) n.r. 2 (0.8%)
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Table 4 Comparative summarized data of patients from the so far largest published case studies for PG between
1985 to 2011 [1-3,18,19] (Continued)
Hodgkin’s lymphoma n.r. n.r. n.r. 0 1 (1.0%) 0
Myelofibrosis n.r. n.r. n.r. 0 1 (1.0%) 0
Large granular lymphocytic
leukaemia
n.r. n.r. n.r. 0 1 (1.0%) 0
other Non-Hodgkin’s
lymphoma
n.r. n.r. n.r. 0 1 (1.0%) 0
n. r. = not reported.
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spectively analyzed data from 49 patients with PG from
our dermatologic wound care center. Our results showed
that only 6% of patients had chronic inflammatory bowel
disease, 22.4% patients had a malignancy, 18.4% had
elevated creatinine levels and 42.8% had anemia. A
potentially relevant aspect that has received little attention
so far was an association with endocrine disease in 38.8%
of patients. Moreover 28.6% of our patients had diabetes
mellitus. Given that 32.6% of patients were obese, we
considered a potential association with metabolic syndrome
as a possible new risk factor for PG [19].
The largest clinical trial to date was published by
Binus et al. with 103 patients in 2011 [18]. Patient data
were taken from the research patient data repository of a
General Hospital in Massachusetts from 2000 to 2007
and retrospectively analyzed. In this study 34% of
patients had an inflammatory bowel disease, 29.1% had
arthritis, and 20.4% had a hematologic disorder, including
monoclonal gammopathy of undetermined significance
(MGUS, 9.7%) and hematologic malignancies (10.7%) like
myelodysplastic syndrome, polycythemia vera, Hodgkin’s
lymphoma, myelofibrosis, acute myelocytic leukaemia,
large granular lymphocytic leukemia, multiple myeloma,
and other Non-Hodgkin’s lymphoma. An underlying
diabetes mellitus was found in 28.2% of all patients.
Another 3.9% of all patients were diagnosed with chronic
Hashimoto thyroiditis. Only 25.2% of the patients in this
collective had none of the common comorbidities. The
outcome of this study was an overall higher occurrence of
associated illnesses in women (risk ratio = 1.2:1).
Another retrospective cohort study in 2012 by
Langan et al. determined incidence, mortality of PG and
the strength of the to date reported possible associations
by analyzing a large, representative UK database [6].
Patients with pyoderma gangrenosum and 3 separate
groups of age-, sex-, and practice-matched controls of the
general population, patients with rheumatoid arthritis (RA),
and patients with inflammatory bowel disease (IBD) were
included in the study. In all there were 313 people with a
median age of 59 years. The risk of death in their results
was three times higher than that for general population con-
trols (adjusted hazard ratio (ahr) = 3.03, 95% CI 1.84-4.73,p < 0.001), 72% higher than that for IBD controls
(ahr = 1.72, 95% CI 1.17-2.59, p = 0.013), with a borderline
increase compared to RA controls (adjusted hazard
ratio = 1.55, 95% CI 1.01-2.37, p = 0.045). Disease associa-
tions were present in 33% of all participants: IBD, n = 67
(20.2%); rheumatoid arthritis n = 39 (11.8%) and
hematologic disorders, n = 13 (3.9%). These results are
consistent with our findings with regard to the underlying
comorbidities even though the presence of IBD was less
in our data.
In contrast to earlier studies, we found that only 9.3%
of patients had chronic inflammatory bowel disease or
rheumatoid arthritis (Table 4) [1-3,6,18,19]. The reasons
for these differences are not clear. The advantage of a
multicenter study however is that possible bias is likely
less than in a single center study.
An important confirmation of previously published
data was the association with hematologic neoplasia. In
contrast to the results from Bolognia et al., who reported
an association in up to 25% with neoplasms, 8.5% of our
patients had an internal neoplasm and another 3.9% of
the patients had a history of hematologic neoplasia,
bringing the total to 12.4% of patients with potentially
associated neoplasia [29]. As a new aspect we observed a
potential association between endocrine diseases and
PG. Diabetes mellitus, mostly type II, was found in
25.5% of patients and hypothyroidism in 6.9%. In this
study 28.6% of patients had diabetes mellitus.
Our results also showed a potential association with
elevated creatinine levels in 20.1% of the patients, and
renal failure in 4.3% of our patients. Anemia was
detected in 45.6% of patients (Table 2). This is another,
as yet unpublished, possible cofactor in the pathogenesis of
PG. The rates reported for diabetes mellitus vary between
the different clinical studies. This may be the result of
studies being performed in different countries, at different
times and thus with different patient populations. Another
factor is that in retrospective analyses only those data may
be analyzed which were initially collected and reported.
Until now association between PG and diabetes mellitus or
metabolic syndrome has only been suggested by Binus et al.
in 2011 and in our own study in 2012 [18,19]. Because of
methodical problems in a retrospective analysis it is
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and that the actual rates may be much higher.Strengths and limitations
One limitation of this multicenter, retrospective study
is the question whether the diagnosis of a PG was
correct in each case, because up to now there exist
no worldwide accepted and standardized diagnostic
criteria. Therefore every investigator of this study is
an expert in dermatology, worked in a leading position in
a dermatologic wound care center and had long lasting
experience in the diagnosis of immunologic skin ulcers,
which may reduce these errors.
Nevertheless, selection bias cannot be fully excluded due
to our recruitment limited exclusively to wound care centers
in dermatologic departments. In Germany PG is an integral
part of dermatologic diagnoses. Therefore, if a wound is
suspected as a PG, nearly all patients - independent of
wound size or other factors - are referred to a dermatologic
wound care center. The participating wound care centers in
this study do not represent all of Germany’s wound care cen-
ters. However we consider the data to reflect a representative
cross section of the PG population in Germany. The different
number of reported patients from the several centers is based
on methodological aspects and does not automatically
correlate to total number of patients with PG treated
in recent years in those centers. Another limitation is
that for some patients the obtained medical history
was incomplete. Therefore we can not exclude that at
least some of the described associated comorbidities
are the result of prior treatment of the PG. Moreover
it is well known that a retrospective study based on a
questionnaire can never include all relevant factors as
well as a prospective investigation.Conclusions
This study, with a total amount of 259 patients with
PG, represents the one of the largest studies of potentially
associated factors and comorbidities in PG worldwide. Our
data demonstrate a possible association with endocrine
disorders, in particular the metabolic syndrome, which
should be taken into consideration in future diagnostic
and therapeutic investigations and protocols. Even
though current data on the relationship between wound
healing disorders and metabolic syndrome are scant,
further studies are desirable, especially on the relationship
between serologic concentrations of inflammatory
mediators such as adipokines and wound healing [30,31].
Furthermore we observed until now not described
possible associations with anaemia and renal dysfunc-
tion. These new data can be the base for standardized
guidelines for the diagnosis and treatment of patients
with PG in the future.Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
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